All Bayer articles – Page 3
-
-
Business
UK objects to pesticide ban in gardens
Government disagrees with EU neonicotinoid moratorium, but will implement it
-
BusinessCarbon nanotubes not commercially viable for Bayer
Company terminates Baytubes project and seeks to divest its know-how in the area
-
Business
Bayer buys Conceptus for $1.1bn
Deal gives German pharma giant access to surgery-free permanent birth control procedure
-
BusinessEU proposes neonicotinoid pesticide ban
Clothianidin, thiamethoxam and imidacloprid at centre of debate over declining bee populations
-
Business
Vasella to leave Novartis in August
Long serving chair of the board of directors will be succeeded by Jörg Reinhardt
-
BusinessIndia pushes for emergency drug licences
Government looks set to force licensing of three patented cancer drugs
-
News
EU food agency links pesticides to bee decline
Agency says neonicotinoids should only be used on crops bees avoid but agrichemical companies dispute its findings
-
Business
Schiff seals deal with Reckitt
Boards approves $1.4 billion Reckitt offer as Bayer pulls out of running
-
Business
Reckitt steps into Schiff deal
Higher bid could sink Bayer’s $1.2bn attempt to buy vitamins and nutritional supplements company
-
BusinessWhat lies within
Bayer boss Marijn Dekkers aims to increase impact of good R&D across different internal units
-
Business
Bayer and Evotec team up on endometriosis
German collaboration aims to develop three drug candidates in five years
-
Business
Regorafenib approved in US
Stivarga tablets approved for treatment of advanced colorectal cancer
-
Business
Bayer $145 million animal health deal
Move will strengthen anti-infective portfolio and introduce reproductive hormones
-
Business
Bayer buys crop protection firm for $425m
Bayer has struck a deal to buy US pest control products firm AgraQuest
-
Business
Light materials from Bayer
Bayer has launched a lightweight material designed to replace steel in railway locomotive and carriage construction
-
News
India green lights production of patented cancer drug
For the first time India has invoked a ‘compulsory licence’ clause to cut the cost of a patented anti-cancer drug
- Previous Page
- Page1
- Page2
- Page3
- Next Page